All WuXi Biologics articles
-
ArticleAccelerating consistent, stable cell line development with targeted integration
Experts from WuXi Biologics explain how next-generation cell line development with targeted integration advances the field by enabling the production of clonal cell lines with predictable transgene copies at specific, predefined sites in the host genome.
-
NewsWuXi Biologics partners with HanchorBio on next-gen immunotherapies
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
-
NewsWuXi Biologics granted novel authorisation for commercial biologic manufacturing in Ireland
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
-
NewsConstruction begins on new WuXi microbial manufacturing site
The new manufacturing site features automation capabilities to ensure efficient production and supports advancement of potential next-generation microbial therapies.
-
NewsWuXi facility boosts bioprocessing capacity with new bioreactors
The new installation increases capacity at WuXi Biologics’ Hangzhou manufacturing facility from 8,000L to 23,000L.
-
NewsWuXi Biologics achieves large-scale manufacturing milestone
The environmentally-sustainable inaugural manufacturing run at WuXi Biologics’ GMP-certified facility in Ireland combined four 4,000-litre single-use bioreactors.
-
NewsGlobal cell line development to surge in next decade
Increased production of biologic drugs in the global cell line development market is anticipated to bring “significant growth” for mammalian cell line development between 2023-2033, a report shows.
-
NewsNew manufacturing facilities to enhance bioconjugate industry
Following WuXi Biologics’ proposed spin-off of its subsidiary, WuXi XDC has launched new manufacturing facilities that enable doubled capacity antibody intermediates and bioconjugate drug substances.
-
NewsWuXi Biologics proposes spin-off to support bioconjugate development
WuXi Biologics proposed spin-off and a separate HKEX listing of its subsidiary WuXi XDC means the company will be able to better capture the fast-growing global bioconjugate market.
-
NewsGSK to pay $40 million to license multiple T cell engagers
A $40 million agreement will enable GSK to exclusively license up to four bi- and multi-specific T cell engaging antibodies.